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Using a general practice research database with general practitioner (GP) clinical records, it
has been observed that among the 617,280 subjects registered with 400 Italian GPs, 15,229
(2.47%) patients were suffering from chronic obstructive pulmonary disease (COPD). Of these,
67.7% had a chest radiograph at least once in a period of 10 years (1997e2006), while in the
same period only 31.9% had a spirometry, 29.9% had a visit to a specialist, and 0.94% had a visit
to an allergologist. From 1997 to 2006, 7.5% of patients with COPD, especially the oldest ones,
were hospitalized at least once for the disease, although 44.0% of all patients with COPD were
hospitalized for other pathologies. With regard to treatment, in 2006, 10,936 (71.1%) of COPD
patients received at least one drug for their disease (drugs classified within the R03 thera-
peutic pharmacological subgroup of the Anatomical Therapeutic Chemical Classification). In
particular, salmeterol/fluticasone was prescribed 6441 times, tiotropium 4962, theophylline
3142, beclomethasone 2853, salbutamol 2256, formoterol 2191, salbutamol/beclomethasone
2129, oxitropium 1802 and formoterol/budesonide 1741 times. Based on these findings, the
level of COPD management in Italy seems to fall short of recommended international COPD
guidelines. In particular, it appears that GPs usually prescribe treatment without the use of
spirometry, and/or without taking into account the severity of airway obstruction. It must also
be noted that, in general, patients with COPD are undertreated.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Treatment of chronic obstructive pulmonary disease (COPD)
is codified by national and international guidelines.1e339 02 72596621.
iroma2.it (M. Cazzola).
8 Elsevier Ltd. All rights reservedThese guidelines have been widely disseminated,4 but,
unfortunately, they do not seem to have an impact on
clinician behaviour4,5 and evidence suggests that COPD still
remains an underdiagnosed and undertreated disease
worldwide.6e14
Some of the factors contributing to this are a poor
knowledge and low adherence to guideline recommenda-
tions, on the part of some health care professionals, and.
Table 1 COPD patient characteristics.
Variable N
Total 15,229
Male sex 9294
Female sex 5935
Age categories (years)
0e49 1567
50e69 4977
70þ 8685
Smoking status
Former smoker 3886
Current smoker 7211
Data not available 4132
Body mass
index (kg/m2)
18< 123
18e24 3192
25e29 4237
30> 3006
Data not available 4671
Primary care of COPD patient in Italy 583a lack of understanding of the significance and severity of
the disease, on the part of patients.15 However, COPD is
both preventable and treatable when it is diagnosed early
and treated effectively.1,2
Primary care clinicians can play a crucial role in early
diagnosis of at-risk subjects.15 They have a unique oppor-
tunity to identify patients at risk through directed
screening, to implement primary and secondary prevention
strategies, and to provide care that encompasses a holistic
approach to management.16 Nonetheless, even after the
publishing and distributing of guideline documents, there is
a very poor understanding of COPD in primary care,17 with
important deviations from current guidelines in general
practitioners (GPs).
Since the impact of national education and literature in
the native language is important and implementation
projects of COPD guidelines should take deviations from the
guidelines that may be specific for each country into
account,6 the aim of this research was to assess whether
current primary care practice in Italy is consistent with the
guidelines for COPD management.
Material and methods
Collection of information
We conducted a population-based retrospective study
using information obtained from the Health Search data-
base (HSD) owned by the Italian College of General
Practitioners (SIMG). The HSD contains patient demo-
graphic details, medical records (e.g. diagnoses, tests and
tests results, hospitalization, etc.), drug history and
prevention records. The software system used codes all
the diagnostic records using the ninth revision of the
International Classification of Diseases (ICD-9).18 The
participating GPs use the same software to record data
during their daily practice, and they agree to send peri-
odically complete, but anonymous, records of their
patients to the HSD. A unique patient code links demo-
graphic and prescription information, clinical events and
diagnoses, hospital admission, and cause of death.
Prescription records are coded according to the last
version of Anatomical Therapeutic Chemical classification
system.19 Data are subject to a range of quality checks.
Any variations within agreed ranges are investigated and
submitted to each participating GP. Physicians who fail to
meet standard quality criteria are not considered for
epidemiological studies.20
For this study, 400 GPs with a list of patient population
of 617,280 individuals at the end of December 2006, were
selected to be representatives of the whole Italian pop-
ulation and also because they ensured the required data
quality.
Ascertainment of COPD and drug prescription
Cases of COPD were identified on the basis of the ICD-9
code (491, 492, 496). All drugs prescribed were abstracted
and codified according to the R03 therapeutic pharmaco-
logical subgroup (drugs for obstructive airway diseases) of
the Anatomical Therapeutic Chemical Classification.Results
Population characteristics
The total sample included 15,229 (2.47% of the entire
population) subjects suffering from COPD who were recor-
ded by participant physicians during the period 1997e2006.
The main features of the study sample are described in
Table 1. The age-specific prevalence of COPD increased,
widening the difference, especially in the elderly both in
males and females. However, it should be pointed out that
COPD was also diagnosed in 690 patients aged between
0 and 40 years. Of our patients, 25.5% were smokers and
47.4% ex-smokers but smoking history was missed in 27.1%,
and this is surprisingly for patients who were diagnosed
with COPD.
COPD assessment
Chest radiograph was the most common diagnostic test
performed (Table 2). In fact, 10,310 (67.7%) of all COPD
patients had a chest X-ray at least once in a period of 10
years (1997 to 2006), while in the same period only 4854
(31.9%) had a spirometry because of COPD and other 1272
for a reason other than COPD, 4554 (29.9%) were referred
to a pulmonary disease specialist because of COPD and
other 1275 for a different reason, and 0.94% had a visit to
an allergologist. From 1997 to 2006, 1137 (7.5%) of the
examined COPD population, especially the oldest ones,
were hospitalized at least once for the disease, although
5566 of all patients with COPD were hospitalized for
diseases other than COPD (Table 3).
Use of drugs
Overall, in 2006, 10,936 (71.1%) patients received at least
one drug for their disease. In particular, salmeterol/
Table 2 Most frequently used diagnostic procedures to
assess COPD.
Diagnostic procedure N
Spirometry
because of COPD 4854
for a different reason 1272
Chest X-ray
because of COPD 6030
for a different reason 4274
Referral to a pulmonary
disease specialist
because of COPD 4554
for a different reason 1275
Referral to an allergologist
because of COPD 143
for a different reason 527
Table 4 Prescription of the most-used active agents of
the R03 group in 2006.
Active agent Prescriptions (N )
Salmeterol/fluticasone 6441
Tiotropium 4962
Theophylline 3142
Beclomethasone 2853
Salbutamol 2256
Formoterol 2191
Salbutamol/beclomethasone 2129
Oxitropium 1802
Formoterol/budesonide 1741
Fluticasone 1185
Budesonide 1113
Salmeterol 921
Ipratropium bromide 870
Doxofylline 864
Flunisolide 567
Montelukast 516
Bamifylline 507
Fenoterol 204
Fenoterol/ipratropium 168
584 M. Cazzola et al.fluticasone was prescribed 6441 times, tiotropium 4962,
theophylline 3142, beclomethasone 2853, salbutamol 2256,
formoterol 2191, salbutamol/beclomethasone 2129, oxi-
tropium 1802 and formoterol/budesonide 1741 times
(Table 4). It should be noted that on the whole there were
5718 prescriptions for inhaled corticosteroids (beclome-
thasone, fluticasone, budesonide, and flunisolide) in mon-
otherapy, in addition to 10,331 prescriptions of an inhaled
corticosteroid in association with a b2-agonist, and 516
prescriptions for montelukast, whereas there were 8074
prescriptions for long-acting bronchodilators in mono-
therapy and 5132 prescriptions for short-acting bronchodi-
lators. In regard to the groups of drugs administered,
a greater proportion of long-acting b2-agonists, inTable 3 Hospital admission and emergency room visits.
N
Hospital admission
Because of COPD 1137
age categories (years)
0e59 109
60e79 603
80þ 425
For a different reason 5566
age categories (years)
0e59 860
60e79 3105
80þ 1601
Emergency room visits
because of COPD 89
age categories (years)
0e59 7
60e79 55
80þ 26
For a different reason 934
age categories (years)
0e59 162
60e79 515
80þ 258monotherapy or in combination with an inhaled cortico-
steroid, were used compared with long-duration
anticholinergics.
Discussion
To the best of our knowledge, this is the first study that
reports the diagnostic accuracy of COPD registers and
evaluates guideline adherence in the management of
stable COPD in primary care in Italy. Our data clearly
indicate that there has been no practical implementation
of COPD guidelines by Italian GPs, although we believe that
the behaviour of our physicians cannot be judged truly
wrong.
First of all, we must highlight that the majority of our
findings match perfectly with what has been observed
worldwide.6e14 COPD guidelines in some practice settings
have progressed from passively diffused documents pub-
lished in professional journals to more active implementa-
tion. Despite these efforts, physician and organizational
practice patterns continue to resist change and are reluc-
tant to rapidly adopt guideline recommendations, because
of multiple barriers that are only beginning to be under-
stood.5 The three-part mission of COPD guidelines includes
systematic development, dissemination, and implemen-
tation. However, until recently, most COPD guideline
developers have created hard-to-adopt, non-explicit
recommendations using informal consensus methods or
expert opinion. Most have only disseminated their guide-
lines through publication in subspecialty journals rather
than reaching frontline physicians through multiple media
and forums. And most guideline developers have not
created effective implementation strategies. Conse-
quently, little evidence has shown that COPD guidelines
have affected health care processes or improved respira-
tory health.21
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suggested that many GPs are not fully aware of the
importance of symptoms and risk factors for COPD.22
Moreover, only few GPs use spirometric criteria to define
COPD,7 although multiple international guidelines that have
addressed the diagnosis of COPD1e3 recognize spirometry as
the ‘‘gold standard’’ for confirming the presence of irre-
versible airflow limitation. Nonetheless, we must honestly
report that many now recommend that spirometry to
detect COPD be used only for current or former smokers
seen in medical care settings who have a high probability of
COPD, as determined by a questionnaire that includes age,
body mass index (obesity indicating a lower risk of COPD),
pack-years of smoking, dyspnea on exertion, wheeze, and
a history of allergies (indicating a lower risk of COPD).23,24
In our COPD population, spirometry was performed for
only one third of the cases. This finding fits perfectly with
the results of the National Committee for Quality Assurance
(NCQA) study25 that suggested that approximately 32% of
a broad range of patients with a new COPD diagnosis had
undergone spirometry within the previous 2 years to 6
months following diagnosis. In addition, spirometric testing
appeared to decrease with increasing age.
It is difficult to explain the reluctance of GPs to refer
their patients with suspected diagnosis of COPD with
spirometry. A study, which investigated the degree of use of
spirometry to establish the diagnosis of COPD in Italy by
using a standardised questionnaire that has been self-
administered to a sample of 2425 Italian GPs,26 reported
that 30% of GPs do not use spirometry to establish the
diagnosis of COPD. The main reasons given for the failure to
use spirometry were that spirometry is not necessary for
the diagnosis of COPD or there are logistical limitations to
the access of the patients to lung function laboratories. An
US survey,27 which sought to identify management prob-
lems that constrain the ability of primary care physicians to
better diagnose and manage COPD, documented that
physicians do not believe that they have time to adequately
assess the disease using spirometry; specifically, they feel
that they have little or no chance to affect patients’
smoking-cessation rates because of the rigid and compact
schedule required of the modern medical practice. Another
Italian study, which evaluated whether office spirometry by
GPs is feasible and may improve the diagnosis of asthma
and COPD,28 documented that a conventional evaluation of
patients with symptoms of chronic airways obstruction
including a detailed questionnaire and physical examina-
tion is not inferior to a conventional evaluation plus office
spirometry, although a type II error cannot be excluded,
since the enrolment of participating patients reached only
about half of the goal determined by a priori sample size
calculations. Moreover, the study showed that where the
general practice is organized as in Italy (on an individual
basis without nursing or technical assistance), office
spirometry is feasible; but even when automated simple
and reliable devices are available along with technical
instruction at the start, regular application tends to
decrease progressively within a few months if there are no
reinforcing recalls or retraining, despite a favourable rating
on usefulness. Yet the GPs should be aware that there is
documentation that incorporation of spirometry testing
into family medicine practices leads to spirometry testingwith acceptable levels of technical quality and concordant
interpretation and is followed by management changes for
almost half of the patients.29
Chest radiograph was the most common diagnostic test
performed. In fact, 67.7% of our COPD patients had a chest
X-ray at least once in a period of 10 years. This figure
indicates that Italian GPs overutilize chest X-ray, but it is
difficult to affirm that this diagnostic behaviour is really
wrong. In any case, this finding is in agreement with the
conduct of Spanish GPs,30 although it contrasts with the
behaviour of GPs in other countries. For instance, in 2005
few British GPs thought that a chest radiograph was
essential.31 In fact, an abnormal chest X-ray is rarely
diagnostic in COPD unless obvious bulbous disease is
present, although guidelines highlight that it is valuable in
excluding alternative diagnoses and establishing the pres-
ence of significant comorbidities, such as cardiac failure.1,3
Nonetheless, chest radiography is a valuable, inexpensive
means of diagnosing moderate-to-severe emphysema.
Correct recognition of emphysema on chest radiography
would be equally valuable in patients who do not have or
are not known to have COPD.32 This is quite likely to occur
in clinical practice because chest radiographs are often
taken for reasons other than a chronic respiratory illness. If
the chest radiograph of one such patient meets the criteria
for emphysema, it is likely that the disease is present and
the patient should be tested for airflow obstruction. Should
the patient be a smoker, the diagnosis of emphysema would
be a particularly strong indication for giving up smoking
since the lungs of such patients are overtly damaged by
inhaled smoke.
One third of the COPD patients were referred to
a pulmonary disease specialist because of COPD. This does
not seem to be inappropriate behaviour. NICE guidelines2
highlight that a specialist opinion may be helpful at any
stage of the disease. Referral may be to establish the
diagnosis, to exclude other pathology, to reassure the
patient, to reinforce the need to stop smoking, to optimise
treatment, or to assess the need for the more complex and
expensive therapies appropriate to severe COPD. However,
International Primary Care Respiratory Group Guidelines28
are more conservative. They recommend that referral to
a specialist should be considered only if therapy appro-
priate to the stage of the patient’s disease does not control
symptoms. The problem is that, historically, assessment of
COPD severity is based on the patient’s level of symptoms,
but also, and mainly, on the severity of the spirometric
abnormality,1e3 and, as stressed before, in our COPD pop-
ulation, spirometry was performed for only one third of the
cases. Consequently, the stage of the disease was unknown
in many patients.
All guidelines highlight that smoking cessation is the
single most effective and cost-effective way to reduce
exposure to COPD risk factors.1e3 Although almost half of
the examined patients were current smokers, the HSD did
not offer any information on attempts to help people to
stop smoking. This is an important lack of information
because there is strong evidence that GPs are an important
source of smoking cessation advice.33 In any case, we must
stress that a survey has documented that Italian GPs do not
often take action against smoking likely because the
percentage of current smokers among them is high and,
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accept their advice.34
The current GOLD guidelines3 recommend that an
inhaled corticosteroids be added to bronchodilator therapy
only for COPD patients at stages III (severe) and IV (very
severe), who are those with an FEV1/FVC ratio< 0.70 and
an FEV1< 50% of predicted still having exacerbations.
Nonetheless, over-treatment with inhaled corticosteroids
was apparent in our patients. The lack of spirometric data
for many patients does not allow us to verify whether those
who received inhaled corticosteroids met the guideline
criteria. In any case, over-treatment with inhaled cortico-
steroids concurs with the work by Decramer et al.,6 who
revealed that 49% of GPs prescribed inhaled corticosteroids
to all of their COPD patients. Also Jones et al.35 have
recently reported an evident over-treatment with inhaled
corticosteroids in primary care. Over-treatment suggests
a waste of resources and puts patients at risk of adverse
effects.36 Nonetheless, we wish to highlight that, although
historically, the severity of COPD has been classified
according to FEV1, which may not correlate directly with
symptoms, a symptomatic approach to therapy using clin-
ical stages may be more useful. Consequently, physicians
should individualize treatment and try an additional type of
drug if the patient symptomatically needs to try something
else, and yet stop the additional drug if it does not seem to
help.37 Plausibly, this is what has been done by our GPs,
most likely on empirical basis.
Also consumption of long-acting bronchodilators was
relatively low, mainly if we think about the recommenda-
tions in the guidelines.1e3 This was an inexplicable
prescriptive behaviour considering that bronchodilators are
the cornerstone of COPD therapy. A volume of published
evidence sustains the role of long-acting bronchodilators in
the treatment of stable COPD. These agents not only induce
prolonged bronchodilation, but also translate this action
into other health-outcome measures that relate to quality
of life, such as the severity of dyspnea, exercise capacity,
and exacerbations.38 In any case, it has been reported that
practices in primary care varied substantially in prescribing
long-acting bronchodilators. The proportion of patients
prescribed with long-acting b2-agonists ranged between
23% and 56% in different practices, and between 9% and 25%
for long-acting anticholinergics in the Devon (UK) primary
care audit.35 Moreover, a US survey centered on COPD case-
vignettes documented that physicians in primary care
settings seemed unclear about the appropriate role of long-
acting bronchodilators.12 Only 35% of them chose a long-
acting bronchodilator when a short-acting agent had failed.
A third of physicians also chose a combination short-acting
bronchodilator. It must be mentioned that in regard to the
groups of drugs administered, a greater proportion of long-
acting b2-agonists, in monotherapy or in combination with
an inhaled corticosteroid, were used compared to long-
duration anticholinergics. This finding concurs with
Miravitlles et al.39 who reported that the prescription of
long-acting b2-agonists was more frequent than tiotropium
in a group of Spanish GPs.
Consumption of leukotriene receptor antagonists was
low, but greater than was to be expected in view of the fact
that their effectiveness in the treatment of COPD is very
limited.40 Also the prescription of methyl-xanthines(theophylline, doxofylline, and bamifylline) was greater
than was to be expected. In fact, theophylline, which used
to be part of the mainstay of treatment for COPD, has been
relegated to third-line therapy in COPD guidelines because
of the frequency of side effects and relative low effi-
cacy.1,3,41 Nonetheless, we do not believe that the use of
methyl-xanthines is a major violation of guidelines.
Theophylline is inexpensive and still has its role. In fact, it
tends to be added to these inhaled bronchodilators in more
severe patients and has been shown to give additional
clinical improvement when added to a long-acting b2-
agonist.42,43
It must be highlighted that the Italian College of
General Practitioners (SIMG) carried out a study to inves-
tigate the degree of control of physician-diagnosed asthma
and COPD in Italy between April 2002 and May 2002 using
data from questionnaires filled in by the GPs.44 In most
COPD patients (66.2%), the level of severity was defined
according to symptom frequency together with the level of
airflow obstruction measured by spirometry. However in
24.9% of cases the physician used only the symptom
frequency as a measure of severity and, furthermore, in
8.9% of cases the physician used only the level of airflow
obstruction as measured by spirometry. Considering only
the patients with a diagnosis of moderate-to-severe COPD
(nZ 4985), no more than 2425 (48.6%) were treated with
long-acting inhaled b2-agonists together with inhaled
corticosteroids according to the GOLD guidelines. Around
half (50.3%) of all patients had at least one specialist visit
in the 12 months before their entry into the study. The
percentage of patients with at least one severe exacer-
bation (defined as hospitalization or emergency room visit
or intensive care unit in the 12 months before their entry
into the study) were, respectively, 17.5% (hospitaliza-
tions), 12.5% (emergency room visits) and 1.2% (intensive
care unit admissions).
It appears that, after four years, Italian GPs have
reduced the use of spirometry for diagnosis of COPD,
diminished the number of consults with a pulmonary
disease specialist because of COPD, and started to use
tiotropium. In addition, fewer patients have been hospi-
talized. Apparently, these findings, apart from the reduced
use of spirometry, indicate an improved approach to the
treatment of COPD by GPs. The problem in trusting this
conclusion is that responses given to questions included in
a questionnaire do not always represent the actual conduct
of the interviewed doctor, whereas the use of a population-
based general practice database allows to study a real life
clinical setting. Consequently, we believe that what we
have described in the present study offers a more realistic
picture of the behaviour of Italian GPs in relation to
patients suffering from COPD, also considering that
comparative analyses have demonstrated the validity of the
information gathered in the HSD.45
In conclusion, our results contribute to outline the
pattern of COPD management by Italian GPs. Above all, our
data indicate that management of stable COPD in primary
care in Italy does often not correspond to guidelines. In
particular, it appears that GPs usually prescribe treatment
without the use of spirometry, and/or without taking into
account the severity of airway obstruction. This finding fits
with what has been documented in other countries,6e14 and
Primary care of COPD patient in Italy 587points out the need to generate recommendations that
could be truly accepted by all and not only by academics
and specialists.
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